CSIMarket
 
Quoin Pharmaceuticals Ltd   (NASDAQ: QNRX)
 
Price: $7.0000 $0.10 1.449%
Day's High: $7.130000114440918 Week Perf: 3.09 %
Day's Low: $ 6.44 30 Day Perf: 40.85 %
Volume (M): 22,443 52 Wk High: $ 41.80
Volume (M$): $ 0 52 Wk Avg: $8.42
Open: $6.92 52 Wk Low: $3.25



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 6
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -19
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Quoin Pharmaceuticals Ltd is a privately held, research-driven pharmaceutical company that specializes in the development and commercialization of innovative and affordable pharmaceutical products for the global market. The company is committed to creating high-quality and effective products that meet the needs of patients and healthcare professionals.

The company was founded in 2016 and is headquartered in Hyderabad, India. It has a team of experienced professionals who are dedicated to scientific research, clinical development, regulatory affairs, manufacturing, and commercialization. Quoin Pharmaceuticals focuses on developing drugs in a wide range of therapeutic areas, including oncology, pain management, dermatology, and neurology.

One of the main objectives of Quoin Pharmaceuticals is to improve patient outcomes, and the company does this by investing heavily in R&D. It has a state-of-the-art research facility that is equipped with cutting-edge technology and equipment, enabling it to discover new drugs, study their mechanisms of action, and develop effective treatment strategies.

The company has a strong focus on quality and compliance, and it strictly adheres to international standards and regulations. All its products are manufactured in certified facilities that meet the highest quality and safety standards.

Quoin Pharmaceuticals has an extensive global network of partners, including contract manufacturers, research institutions, and distribution companies. This enables the company to leverage its resources to deliver innovative drugs and cutting-edge healthcare solutions to markets around the world.

Quoin Pharmaceuticals has a strong commitment to sustainability and social responsibility. It recognizes the importance of giving back to the community, and it supports a range of initiatives in education, healthcare, and environmental conservation.

Overall, Quoin Pharmaceuticals is a dynamic and innovative pharmaceutical company that is dedicated to improving patient outcomes by developing safe, effective, and affordable drugs.


   Company Address: 42127 Pleasant Forest Court Ashburn 20148 VA
   Company Phone Number: 980-4182   Stock Exchange / Ticker: NASDAQ QNRX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ARDX   -4.56%    
ISCO   -5.56%    
LGVN   -57.12%    
OVID        2.85% 
RGBP   -50%    
SBFM   -17.58%    
• View Complete Report
   



Clinical Study

Quoin Pharmaceuticals Pioneering New Frontiers in Rare Disease Therapeutics

Published Wed, Oct 29 2025 7:09 PM UTC

Breaking New Ground in Pediatric Netherton Syndrome Quoin Pharmaceuticals Ltd., a prominent player in the niche domain of rare and orphan diseases, is making significant strides in advancing clinical research and therapeutic avenues. Recently, the company announced a critical development in its pediatric Netherton Syndrome (NS) study. The ongoing investigator-led study that ...

Clinical Study

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Tr...

Published Sun, Jun 15 2025 10:41 AM UTC

Quoin Pharmaceuticals: Advancing Rare Disease Treatment Frontiers with Novel Rapamycin Formulations and Positive Netherton Syndrome Study OutcomesASHBURN, Va. In a determined stride towards addressing unmet medical needs in the realm of rare and orphan diseases, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a clinical-stage specialty pharmaceutical company, has announced proli...

Clinical Study

Quoin Pharmaceuticals Pioneers Hope for Rare Genetic Disorders Positive Interim Results in Netherton Syndrome Clini...

Published Sat, Dec 28 2024 5:37 AM UTC

ASHBURN, Va. December 18, 2024 In a groundbreaking development for the treatment of rare genetic diseases, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a clinical-stage specialty pharmaceutical company, has announced positive interim data from two ongoing clinical studies involving Netherton syndrome (NS), a rare inherited genetic disorder. This announcement comes on the ...

Clinical Study

QRX003 Innovation Targeting Aberrant Protease Activity in Netherton Syndrome for Breakthrough Treatment,

Published Thu, Dec 19 2024 1:00 PM UTC

QRX003: A Promising New Approach in the Management of Netherton Syndrome Quoin Pharmaceuticals Ltd. a company distinguished by its commitment to addressing unmet medical needs in rare and orphan diseases, recently received FDA clearance to commence a new clinical trial to evaluate QRX003, a topical lotion designed for the treatment of Netherton Syndrome (NS). This developmen...

Clinical Study

Quoin Pharmaceuticals Advances Clinical Trials for QRX003 A Promising Step Forward in the Fight Against Netherton Syn...

Published Tue, Nov 5 2024 1:00 PM UTC

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a noteworthy player in the realm of clinical-stage specialty pharmaceuticals, has made significant strides in its commitment to developing cutting-edge treatments for rare and orphan diseases. As announced from their headquarters in Ashburn, Virginia on November 5, 2024, the company has commenced clinical testing of its lead product...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.63
Working Capital Ratio 1.63
Leverage Ratio (MRQ) 2.04
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -10.21 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash -
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 838
Net Income per Employee (TTM) -3,110,886
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) 0 %
Net Margin (MRQ) -338867 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Quoin Pharmaceuticals Ltd's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.